Overview

Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients

Status:
Withdrawn

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

The investigators hypothesize that a calcineurin inhibitor-free, steroid-free, co-stimulatory blockade-based immunosuppressive regimen, in combination with a GLP-1 agonist, will reduce the islet mass required to achieve and sustain insulin independence following simultaneous islet-kidney transplantation.

Phase:

N/A

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Bristol-Myers Squibb

Treatments:

Abatacept
Calcineurin Inhibitors
Immunosuppressive Agents